Consensus of the experts of the round table «ARVI therapy in adults: traditional concepts and prospects»


DOI: https://dx.doi.org/10.18565/therapy.2022.10.144-151

Malyavin A.G., Gorelov A.V., Esaulenko E.V., Kalyuzhin O.V., Shikh E.V., Babak S.L., Pchelintsev M.V.

EXPERT COUNCIL:
MALYAVIN A.G., MD, professor, professor of the Department of phthisiology and pulmonology of the Faculty of general medicine of A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia, chief freelance pulmonologist of the Ministry of Healthcare of Russia in the Central Federal District, general secretary of RSMSIM (Moscow)
GORELOV A.V., MD, professor, academician of RAS, professor of the Department of children’s diseases of I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University), deputy director for research at the Central Research Institute of Epidemiology of Rospotrebnadzor (Moscow)
ESAULENKO E.V., MD, professor, head of the Department of infectious diseases in adults and epidemiology of Saint Petersburg State Pediatric Medical University of the Ministry of Healthcare of Russia, head of the laboratory «Viral hepatitis» of Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology of Rospotrebnadzor (Saint Petersburg)
KALYUZHIN O.V., MD, professor, professor of the Department of clinical immunology and allergology of I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University) (Moscow)
SHIKH E.V., MD, professor, head of the Department of clinical pharmacology and propaedeutics of internal diseases of I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University) (Moscow)
BABAK S.L., MD, professor of the Department of phthisiology and pulmonology of the Faculty of general medicine of A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia (Moscow)
PCHELINTSEV M.V., PhD in Medicine, associate professor, associate professor of the Department of clinical pharmacology and evidence-based medicine of Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia (Saint Petersburg)
With the support of: Russian Scientific Medical Society of Internal Medicine (RSMSIM), Russian Association of Allergologists and Clinical Immunologists (RAACI), Society of Clinical Pharmacologists of Russia.
Keywords: bacterial lysates, acetylcysteine, ketoprofen, acute respiratory viral infections, probiotics
Read entire article

Literature

1. Клинические рекомендации. Острые респираторные вирусные инфекции (ОРВИ) у взрослых. Некоммерческое партнерство «Национальное научное общество инфекционистов», Общероссийская общественная организация «Российское научное медицинское общество терапевтов». Рубрикатор клинических рекомендаций Минздрава России. 2021. ID: 724. Доступ: https://cr.minzdrav.gov.ru/schema/724_1 (дата обращения – 01.12.2022). [Clinical guidelines. Acute respiratory viral infections (ARVI) in adults. National Scientific Society of Infectious Diseases, Russian Scientific Medical Society of Internal Medicine. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2021. ID: 724.


URL: https://cr.minzdrav.gov.ru/schema/724_1 (date of access – 01.12.2022) (In Russ.)].


2. Согласованное мнение экспертов IX Образовательного международного консенсуса по респираторной медицине в педиатрии по вопросам применения бактериальных лизатов в педиатрической практике. Доктор.Ру. 2020; 19(3): 61–64. [Consensus opinion of experts of the IX Educational International Consensus on Respiratory Medicine in Pediatrics on the use of bacterial lysates in pediatric practice. Doctor.Ru. 2020; 19(3): 61–64 (In Russ.)]. EDN: ALRYAW.


3. Rossi G.A., Esposito S., Feleszko W. et al. Immunomodulation therapy – clinical relevance of bacterial lysates OM-85. Eur Respir Pulmonary Dis. 2019; 15(1): 17–23. https://dx.doi.org/10.17925/ERPD.2019.5.1.17.


4. Esposito S., Soto-Martinez M.E., Feleszko W. et al. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin Immunol. 2018; 18(3): 198–209. https://dx.doi.org/10.1097/ACI.0000000000000433.


5. Feleszko W., Rossi G.A., Krenke R. et al. Immunoactive preparations and regulatory responses in the respiratory tract: Potential for clinical application in chronic inflammatory airway diseases. Expert Rev Respir Med. 2020; 14(6): 603–19. https://dx.doi.org/10.1080/17476348.2020.1744436.


6. Del-Rio-Navarro B.E., Espinosa-Rosales F.J., Flenady V., Sienra-Monge J.J.L. Cochrane Review: Immunostimulants for preventing respiratory tract infection in children. Evidence-Based Child Health: A Cochrane Review Journal. 2012; 7(2): 629–717. https://dx.doi.org/10.1002/ebch.1833.


7. Yin J., Xu B., Zeng X., Shen K. Broncho-Vaxom in pediatric recurrent respiratory tract infections: a systematic review and meta-analysis. Int Immunopharmacol. 2018; 54: 198–209. https://dx.doi.org/10.1016/j.intimp.2017.10.032.


8. Cao C., Wang J., Li Y. et al. Efficacy and safety of OM-85 in paediatric recurrent respiratory tract infections which could have a possible protective effect on COVID-19 pandemic: A meta-analysis. Int J Clin Pract. 2021; 75(5): e13981. https://dx.doi.org/10.1111/ijcp.13981.


9. Zagar S., Lofler-Badzek D. Broncho-Vaxom in children with rhinosinusitis: a double-blind clinical trial. ORL J Otorhinolaryngol Relat Spec. 1988; 50(6): 397–404. https://dx.doi.org/10.1159/000276020.


10. Sorokman T.V., Moldovan P.M., Popelyuk N.O. et al. [Clinical and immunological efficacy of bacterial lysate OM-85 in children with respiratory tract infection. Aktual’naya infektologiya = Actual infectology. 2020; 8(2): 18–24 (In Ukr.)]. https://dx.doi.org/10.22141/2312-413x.8.2.2020.199731. EDN: CEZKTZ.


11. Zhu H., Zhang H., Hu W. Clinical observation on 60 cases of recurrent respiratory tract infections in children treated by Bronchovaxom combined with routine treatment. China Prac Med. 2015; 10(7): 140–41.


12. Li J., Chen C., Liu Y. Observation on the therapeutic effect of Broncho-Vaxom in treating repeated respiratory tract infection. Acta Academiae Medicinae CPAF. 2008; 13(3): 212–13, 216.


13. Рябова М.А., Галкина О.В., Пестакова Л.В., Пособило Е.Е. К вопросу о лечении острых заболеваний верхних дыхательных путей. Педиатрия. Приложение к журналу Consilium Medicum. 2016; 3: 51–54. [Ryabova M.A., Galkina O.V., Pestakova L.V., Posobilo E.E. The question of treatment of acute diseases of the upper respiratory tract. Pediatriya. Prilozheniye k zhurnalu Consilium Medicum = Pediatrics. Supplement to Consilium Medicum. 2016; 3: 51–54 (In Russ.)]. EDN: XXXAJL.


14. Эдже М.А., Овчинников А.Ю., Хон Е.М. Современные схемы лечения пациентов с острым бактериальным риносинуситом. Consilium Medicum. 2016; 18(11): 63–66. [Edzhe M.A., Ovchinnikov A.Yu., Khon E.M. Current treatment regimens for patients with acute bacterial rhinosinusitis. Consilium Medicum. 2016; 18(11): 63–66 (In Russ.)]. EDN: VVHPYG.


15. Heintz B., Schlenter W.W., Kirsten R., Nelson K. Clinical efficacy of Bronch-Vaxom in adult patients with chronic purulent sinusitis – a multi-centric, placebo-controlled, double-blind study. Int J Clin Pharmacol Ther Toxicol. 1989; 27: 530–34.


16. Kuchar E., Miskiewicz K., Nitsch-Osuch A., Szenborn L. Pathophysiology of clinical symptoms in acute viral respiratory tract infections. Adv Exp Med Biol. 2015; 857: 25–38. https://dx.doi.org/10.1007/5584_2015_110.


17. Kim S.Y., Chang Y.J., Cho H.M. et al. Non-steroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev. 2015; 9: CD006362. https://dx.doi.org/10.1002/14651858.CD006362.pub4.


18. Sarzi-Puttini P., Atzeni F., Lanata L. et al. Pain and ketoprofen: What is its role in clinical practice? Reumatismo. 2010; 62(3): 172–88. https://dx.doi.org/10.4081/reumatismo.2010.172.


19. Rencber S., Karavana S.Y., Ozyazici M. Bioavailability file: Ketoprofen. Fabad J Pharm Sci. 2009; 34(4): 203.


20. Kokki H., Kokki M. Ketoprofen versus paracetamol (acetaminophen) or ibuprofen in the management of fever. Clin Drug Investig. 2010; 30(6): 375–86. https://dx.doi.org/10.1007/BF03256907.


21. Coutinho G., Duerden M., Sessa A. et al. Worldwide comparison of treatment guidelines for sore throat. Int J Clin Pract. 2021; 75(5): e13879. https://dx.doi.org/10.1111/ijcp.13879.


22. Мальцева Г.С., Захарова Г.П., Артемьева Е.С., Рязанцев С.В. Патогенетические аспекты медикаментозной терапии у пациентов с болью в горле. РМЖ. 2018; 26(10): 54–58. [Maltseva G.S., Zakharova G.P., Artemyeva E.S., Ryazantsev S.V. Pathogenetic aspects of drug therapy in patients with sore throat. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2018; 26(10): 54–58 (In Russ.)]. EDN: YRPBET.


23. Mehlisch D.R., Aspley S., Daniels S.E. et al. A single-tablet fixed-dose combination of racemic ibuprofen/paracetamol in the management of moderate to severe postoperative dental pain in adult and adolescent patients: a multicenter, two-stage, randomized, double-blind, parallel-group, placebo-controlled, factorial study. Clin Ther. 2010; 32(6): 1033–49. https://dx.doi.org/10.1016/j.clinthera.2010.06.002.


24. Временные методические рекомендации «Лекарственная терапия острых респираторных вирусных инфекций в амбулаторной практике в период эпидемии COVID-19». Версия 2 (16.04.2020). ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет), ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологи и инфекционных заболеваний» Минздрава России, ФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава России, Минздрав России. Доступ: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/033/original/RESP_REC_V2.pdf (дата обращения – 01.12.2022). [Interim guidelines «Drug therapy for acute respiratory viral infections in outpatient practice during the COVID-19 epidemic». Version 2 (04/16/2020). I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University), National Medical Research Center for Phthisiopulmonologists and Infectious Diseases of the Ministry of Healthcare of Russia, National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of Russia, Ministry of Healthcare of Russia. URL: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/033/original/RESP_REC_V2.pdf (date of access – 01.12.2022) (In Russ.)].


25. Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020; 8(4):e21. https://dx.doi.org/10.1016/10.1016/S2213-2600(20)30116-8.


26. Moore N., Bosco-Levy P., Thurin N. et al. NSAIDs and COVID 19: A systematic review and meta-analysis. Drug Saf. 2021; 44(9): 929–38. https://dx.doi.org/10.1007/s40264-021-01089-5.


27. Zhou Q., Zhao S., Gan L. et al. Use of non-steroidal anti-inflammatory drugs and adverse outcomes during the COVID-19 pandemic: A systematic review and meta-analysis. EClinicalMedicine. 2022; 46: 101373. https://dx.doi.org/10.1016/j.eclinm.2022.101373.


28. Hay A.D., Costelloe C., Redmond N.M. et al. Paracetamol plus ibuprofen for the treatment of fever in children (PITCH): Randomised controlled trial. BMJ. 2008; 337: a1302. https://dx.doi.org/10.1136/bmj.a1302.


29. Gerritsen J., Smidt H., Rijkers G.T. et al. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr. 2011; 6(3): 209–40. https://dx.doi.org/10.1007/s12263-011-0229-7.


30. Кamada N., Nunez G. Regulation of the immune system by the resident intestinal bacteria. Gastroenterology. 2014; 146(6): 1477–88. https://dx.doi.org/10.1053/j.gastro.2014.01.060.


31. Qin N., Zheng B., Yao J. et al. Influence of H7N9 virus infection and associated treatment on human gut microbiota. Sci Rep. 2015; 5: 14771. https://dx.doi.org/10.1038/srep14771.


32. Каннер Е.В., Максимов М.Л., Горелова Е.А., Петров В.А. Современные подходы к коррекции микробиома кишечника у детей при проведении антибактериальной терапии. Медицинский совет. 2016; 1: 102–107. [Каnner E.V., Maksimov М.L., Gorelova E.A., Petrov V.A. Current approaches to correcting the intestinal microbiome in children during antibiotic therapy. Meditsinskiy sovet = Medical Council. 2016; 1: 102–107 (In Russ.)]. EDN: VLQNAD.


33. Ouwehand A.C., Forssten S., Hibberd A.A. et al. Probiotic approach to prevent antibiotic resistance. Ann Med. 2016; 48(4): 246–55. https://dx.doi.org/10.3109/07853890.2016.1161232.


34. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 16 от 18.08.2022. Минздрав России. Доступ: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/060/193/original/%D0%92%D0%9C%D0%A0_COVID-19_V16.pdf (дата обращения – 01.12.2022). [Interim guidelines «Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)». Version 16 of 08/18/2022. Russian Ministry of Healthcare. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/060/193/original/%D0%92%D0%9C%D0%A0_COVID-19_V16.pdf (date of access – 01.12.2022) (In Russ.)].


35. Захарова Н.В. Антибиотикоассоциированная диарея: патогенез, лечение. Врач. 2013; 1: 35–39. [Zakharova N. Antibiotic-associated diarrhea: pathogenesis, treatment. Vrach = The Doctor. 2013; 1: 35–39 (In Russ.)]. EDN: PYRDQJ.


36. Avadhani A., Miley H. Probiotics for prevention of antibiotic-associated diarrhea and Clostridium difficile-associated disease in hospitalized adults-a meta-analysis. J Am Acad Nurse Pract. 2011; 23(6): 269–74. https://dx.doi.org/10.1111/j.1745-7599.2011.00617.x.


37. Sheu B.-C., WU J.-J., LO C.-Y. et al. Impact of supplement with Lactobacillus- and Bifidobacterium containing yogurt on triple therapy for Helicobacter pylori. Aliment Pharmacol Ther. 2002; 16(9): 1669–75. https://dx.doi.org/10.1046/j.1365-2036.2002.01335.x.


38. Chatterjee S., Kar P., Das T. et al. Randomised placebo-controlled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12 for prevention of antibiotic-associated diarrhoea. J Assoc Physicians India. 2013; 61(10): 708–12.


39. Irwin R.S., French C.L., Chang A.B., Altman K.W.; CHEST Expert Cough Panel. Classification of cough as a symptom in adults and management algorithms: CHEST guideline and expert panel report. Chest. 2018; 153(1): 196–209. https://dx.doi.org/10.1016/j.chest.2017.10.016.


40. Борисенок О.А., Бушма К.М. Ацетилцистеин: настоящее и взгляд в будущее. Международные обзоры: клиническая практика и здоровье. 2013; 5: 32–40. [Borisenok O.A., Bushma K.M. Acetylcysteine: the present and a look into the future. Mezhdunarodnyye obzory: klinicheskaya praktika i zdorov’ye = International Reviews: Clinical Practice and Health. 2013; 5: 32–40 (In Russ.)]. EDN: ROQGHJ.


41. Mata M., Sarrion I., Armengot M. et al. Respiratory syncytial virus inhibits ciliagenesis in differentiated normal human bronchial epithelial cells: Effectiveness of N-acetylcysteine. PLoS One. 2012; 7(10): e48037. https://dx.doi.org/10.1371/journal.pone.0048037.


42. Geiler J., Michaelis M., Naczk P. et al. N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol. 2010; 79(3): 413–20. https://dx.doi.org/10.1016/j.bcp.2009.08.025.


43. Roveta S., Debbia E., Schito G., Marchese A. Comparison of the activity of N-acetylcysteine, ambroxol, bromhexine and sobrerol on Staphylococcus aureus biofilms. GIMMOC. 2004; 8: 131–42.


44. Blasi .F, Page C., Rossolini G.M. et al. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir Med. 2016; 117: 190–97. https://dx.doi.org/10.1016/j.rmed.2016.06.015.


45. Chalumeau M., Duijvestijn Y.C. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease. Cochrane Database Syst Rev. 2013; 5: CD003124. https://dx.doi.org/10.1002/14651858.CD003124.pub4.


46. Рубрикатор клинических рекомендаций Минздрава России. Доступ: https://cr.minzdrav.gov.ru (дата обращения – 01.12.2022). [Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. URL: https://cr.minzdrav.gov.ru (date of access – 01.12.2022) (In Russ.)].


47. Государственный реестр лекарственных средств Минздрава России. Лекарственные препараты с МНН ацетилцистеин. Доступ: https://grls.rosminzdrav.ru (дата обращения – 01.12.2022). [State Register of Medicines of the Ministry of Healthcare of Russia. Medicines with INN acetylcysteine. URL: https://grls.rosminzdrav.ru (date of access – 01.12.2022) (In Russ.)].


Similar Articles

Back to Content

Бионика Медиа